ArticleOncoimmunology
Phase I study of glypican-3-derived peptide vaccine therapy for patients with refractory pediatric solid tumors.
Nobuhiro Tsuchiya et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
36 papers cite it
pooled ittrialcites it